Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1CNS 1

Conditions

Prostatic Neoplasms 1Pain 1Oligodendroglioma 1Neoplasm Metastasis 1Gliosarcoma 1Glioma 1Glioblastoma 1Carcinoma, Renal Cell 1Brain Neoplasms 1Astrocytoma 1

Interventions

Temozolomide 29Bevacizumab 12Radiotherapy 10Irinotecan 7Carboplatin 7Carmustine 5Magnetic Resonance Spectroscopy 4Filgrastim 4Cyclophosphamide 4Cisplatin 4Vincristine 3Thiotepa 3Surgical Procedures, Operative 3Peripheral Blood Stem Cell Transplantation 3Etoposide 3talampanel 2sargramostim 2antineoplaston AS 2-1 2antineoplaston A10 2abemaciclib 2Topotecan 2Thalidomide 2Tamoxifen 2Sunitinib 2Radiotherapy, Intensity-Modulated 2Procarbazine 2Immunoglobulin G 2Everolimus 2Drug Therapy 2Doxorubicin 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Oligodendroglioma × tandutinib × Clear all
NCT00667394 2015-11-05

Tandutinib Plus Bevacizumab to Treat Recurrent Brain Tumors

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
42 enrolled 11 charts
CNSSarcoma

Astrocytoma, Brain Neoplasms, Glioblastoma, Glioma, Oligodendroglioma, Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡